Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated at Jefferies Financial Group

Stock analysts at Jefferies Financial Group initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $580.00 price target on the pharmaceutical company’s stock. Jefferies Financial Group’s price target would indicate a potential upside of 17.80% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. Barclays increased their target price on shares of Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an “overweight” rating in a research note on Tuesday, February 17th. UBS Group upped their price target on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a “buy” rating in a report on Monday, January 26th. HC Wainwright raised their price objective on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley reissued an “overweight” rating and set a $570.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Evercore boosted their price objective on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Twenty-three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $553.36.

Vertex Pharmaceuticals Trading Down 1.4%

Shares of VRTX stock opened at $492.38 on Tuesday. Vertex Pharmaceuticals has a 1 year low of $362.50 and a 1 year high of $519.68. The firm’s fifty day simple moving average is $469.19 and its 200 day simple moving average is $436.92. The firm has a market capitalization of $125.08 billion, a P/E ratio of 32.12 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company earned $3.98 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Mark E. Bunnage sold 2,021 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total transaction of $930,529.03. Following the completion of the transaction, the executive vice president owned 12,914 shares in the company, valued at $5,945,993.02. This trade represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Amit Sachdev sold 58,613 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $468.83, for a total value of $27,479,532.79. Following the completion of the sale, the executive vice president owned 58,934 shares in the company, valued at approximately $27,630,027.22. This represents a 49.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 91,156 shares of company stock valued at $42,845,497. Corporate insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VRTX. Earned Wealth Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.3% during the fourth quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock valued at $295,000 after acquiring an additional 21 shares during the period. Confluence Wealth Services Inc. grew its holdings in shares of Vertex Pharmaceuticals by 4.0% in the 4th quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock worth $247,000 after purchasing an additional 21 shares during the last quarter. Williams Jones Wealth Management LLC. increased its position in shares of Vertex Pharmaceuticals by 1.9% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock worth $524,000 after purchasing an additional 21 shares in the last quarter. Childress Capital Advisors LLC lifted its holdings in Vertex Pharmaceuticals by 3.1% during the 4th quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company’s stock valued at $331,000 after purchasing an additional 22 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its holdings in Vertex Pharmaceuticals by 0.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 5,026 shares of the pharmaceutical company’s stock valued at $2,279,000 after purchasing an additional 24 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER data for povetacicept showed a large (~52%) reduction in proteinuria in IgA nephropathy, boosting hopes for an expedited regulatory filing and expansion of Vertex into kidney disease — a clear fundamental catalyst. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Positive Sentiment: Multiple banks raised price targets and reiterated Buy/Outperform ratings after the trial (Morgan Stanley, BofA, Oppenheimer, Citigroup, HC Wainwright, Truist, Jefferies, etc.), increasing analyst upside and supporting further gains. Analyst price target coverage roundup
• Positive Sentiment: Broker commentary and coverage upgrades (e.g., new coverage from Jefferies, maintained/raised ratings at BMO and others) reinforce investor confidence in povetacicept’s commercial potential and Vertex’s pipeline diversification. BMO Capital sticks to Buy rating
• Neutral Sentiment: Company presentations at healthcare conferences (Barclays, Leerink transcripts published) provide management commentary and additional detail for investors, but contain no new trial data beyond the RAINIER release. Barclays conference transcript
• Neutral Sentiment: Coverage in market media noted Vertex’s rising biotech weight in Nasdaq indices and broader attention following the trial — visibility that can attract flows but also raise short‑term trading interest. Biotech focus rises in Nasdaq index
• Negative Sentiment: After the big rally, the stock is pulling back (broader coverage flagged a larger intraday fall vs. the market); this looks like classic profit‑taking/mean reversion after rapid gains, increasing short‑term volatility risk. Vertex registers a bigger fall than the market
• Negative Sentiment: Zacks and other outlets also noted that recent earnings estimate revision trends and any lingering execution questions could temper momentum, so some analysts caution that the upside may be paced by upcoming filings and commercialization visibility. Will this strength last?

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.